zurück
Brivaracetam (new indication: partial onset seizures in patients with epilepsy, adjunctive therapy, patients aged 2 – < 4 years)
Subject:
- Active Substance: Brivaracetam
- Name: Briviact®
- Therapeutic area: Epilepsy
- Pharmaceutical company: UCB Pharma GmbH
Time table:
- Start: 01.03.2022
- Final decision by G-BA: 01.09.2022
Final decision:
- No additional benefit proved